A Phase 2B, 8-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults with DSM-5 Current Cannabis Use Disorder (CUD) Save

Date Added
July 3rd, 2018
PRO Number
Pro00079439
Researcher
Aimee Mc Rae

Silhouette
Keywords
Drug Studies, Substance Use
Summary

This study will examine whether the investigational medication PF-0447845 is safe and effective in reducing cannabis use among people who frequently use cannabis. This is a 12-week, randomized, double-blind, placebo-controlled outpatient clinical trial that will be conducted at 4 research sites in the eastern U.S.

Institution
MUSC
Recruitment Contact
Amanda Wagner
843-792-0484
wagne@musc.edu

Relationships Focus Group Study Save

Date Added
June 5th, 2018
PRO Number
Pro00077597
Researcher
Julianne Hellmuth

Silhouette
Keywords
Alcohol, Substance Use
Summary

The goal of this project is to conduct interviews with 50 Veterans in order to inform the development of a treatment protocol to reduce substance use disorder symptoms and relationship problems simultaneously. Group and individual interviews are expected to last approximately 60-90 minutes.

Institution
MUSC
Recruitment Contact
Gili Ornan
843-792-4009
ornan@musc.edu

Approach bias modification for the treatment of cannabis use disorder Save

Date Added
May 1st, 2018
PRO Number
Pro00077532
Researcher
Brian Sherman

Silhouette
Keywords
Psychiatry, Substance Use
Summary

This study will evaluate the effect of counseling plus Approach Bias Modification on cannabis use and craving in people with cannabis use disorder. The study consists of a screening visit, four treatment visits and a follow-up. Participants will have 4 sessions of counseling, 4 sessions of Approach Bias Modification, and 3 cue reactivity sessions.

Institution
MUSC
Recruitment Contact
Lisa Nunn
843-792-0476
jenkinli@musc.edu

QuitFast: Evaluating transcranial magnetic stimulation as a tool to reduce smoking directly following a quit attempt Save

Date Added
February 6th, 2018
PRO Number
Pro00074769
Researcher
Colleen Hanlon

Silhouette
Keywords
Brain, Psychiatry, Smoking, Substance Use
Summary

The first week after attempting to quite cigarette smoking is the hardest period to succeed. Research shows that individuals able to remain cigarette free for this first week are significantly more likely to quit the smoking habit. In this study, sponsored by the National Institutes of Health, we are evaluating a new tool to assist individuals with quitting cigarette smoking. Transcranial magnetic stimulation (TMS) is a non-invasive technique that uses magnetic pulses to temporarily stimulate specific brain areas (without the need for surgery, anesthetic, or other invasive procedures). This study will test whether 10 daily sessions of TMS over the forehead can help decrease smoking rates in treatment-seeking individuals.

Institution
MUSC
Recruitment Contact
Julia Imperatore
843-792-5560
imperato@musc.edu

Effect of GET73 on magnetic resonance spectroscopy measures of central glutamate and GABA and alcohol cue-elicited brain activation in recently abstinent non-treatment-seeking individuals with Alcohol Use Disorder Save

Date Added
September 26th, 2017
PRO Number
Pro00069862
Researcher
Raymond Anton

Silhouette
Keywords
Alcohol, Brain, Drug Studies, Substance Use
Summary

The purpose of this study is to evaluate the potential mechanism of action and the safety of GET73, a new drug under development for the reduction of craving and drinking in alcohol dependent individuals. The study involves five to six visits over a three to four week period, including one to two assessment visits and two visits during which participants will be assigned to take, in a double-blinded fashion, both GET73 and a placebo (two visits during each condition). During three of these visits, participants will undergo a one-hour MRI scan. Compensation is available for qualified participants.

Institution
MUSC
Recruitment Contact
Katy Fuqua
(843) 792-1452
fuquama@musc.edu

Gabapentin for Bipolar & Cannabis Use Disorders: Relation to Brain GABA/Glutamate Save

Date Added
September 5th, 2017
PRO Number
Pro00069905
Researcher
James Prisciandaro

Silhouette
Keywords
Depression, Mental Health, Psychiatry, Substance Use
Summary

This study examines the effects of the FDA-approved medication Gabapentin among individuals with Bipolar Disorder who smoke marijuana. Participants in the study will take Gabapentin and matched placebo (one at a time) for 5 days each. There are 5 study visits, including 2 MRI scans.

Institution
MUSC
Recruitment Contact
Sara Hix
843-792-0572
bipolardisorder@musc.edu

Progesterone for the treatment of cannabis withdrawal Save

Date Added
May 2nd, 2017
PRO Number
Pro00065954
Researcher
Brian Sherman

Silhouette
Keywords
Psychiatry, Substance Use
Summary

The purpose of the study is to explore the effects of progesterone on cannabis withdrawal in women who regularly smoke marijuana. Participants will be asked to abstain from marijuana use for 5 days after the onset of menses. They will receive 8 doses of either progesterone or placebo during this time. On Days 1 and 5 they will come to the clinic to complete study assessments and provide urine, saliva and blood samples.On Days 2-4 assessments will be completed via text messages, Redcap surveys and video calls. Participants will be monitored for adverse events and cannabis withdrawal on each study day.

Institution
MUSC
Recruitment Contact
Lisa Nunn
8437920476
jenkinli@musc.edu

Imaging Framework for Testing GABAergic/glutamatergic Drugs in Bipolar Alcoholics Save

Date Added
April 4th, 2017
PRO Number
Pro00064964
Researcher
James Prisciandaro

Silhouette
Keywords
Alcohol, Depression, Mental Health, Psychiatry, Substance Use
Summary

This study examines the effects of the medication gabapentin and the supplement n-acetylcysteine among individuals with Bipolar Disorder who regularly drink alcohol. Participants in this study will take gabapentin, n-acetylcysteine, and matched placebo (one at a time) for 5 days each. There are 8 study visits, including 3 MRI scans.

Institution
MUSC
Recruitment Contact
Sara Hix
843-792-0572
hixs@musc.edu

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder Save

Date Added
March 7th, 2017
PRO Number
Pro00062819
Researcher
Susan Sonne

Silhouette
Keywords
Drug Studies, Psychiatry, Substance Use
Summary

This study is designed to evaluate the safety and effectiveness of using two different medications (extended release naltrexone and bupropion) compared to matching placebo (an inactive substance) in the treatment of methamphetamine use disorder. Participants will receive study medications along with brief medication management for twelve weeks, with follow up visits at weeks 13 and 16.

Institution
MUSC
Recruitment Contact
Elizabeth Chapman
864-898-5800
echapman@bhspickens.com

Developing an integrated exposure-based therapy for co-occurring PTSD and substance use among adolescents: Teen COPE focus groups Save

Date Added
December 6th, 2016
PRO Number
Pro00060455
Researcher
Sudie Back

Silhouette
Keywords
Adolescents, Alcohol, Anxiety, Mental Health, Psychiatry, Substance Use
Summary

This study aims to conduct focus groups with adolescents and parents (30 adolescents and 30 parents) to gather feedback to help design an integrated psychological therapy for co-occurring PTSD and substance use among adolescents (Teen COPE). This information will be used to make revisions to the new Teen COPE Therapist Guide and Patient Workbook.

Institution
MUSC
Recruitment Contact
Emma Barrett
843-792-5594
barrette@musc.edu

Change_preferences

-- OR --

Create_login